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Figure 1 • TrkA receptor-mediated 
signal transduction pathways. 
Binding of NGF to TrkA leads to re-
ceptor dimerisation and activation 
through autophosphorylation.Sub-
sequent recruitment of adaptor 
proteins to the different phospho-
tyrosine residues within the TrkA 
molecules results in the activation  
of PI3-K, PLCγ and MAPK signalling 
cascades. Adaptor protein Shc 
activates Ras/Rap1 through Grb-2 
and Sos. Subsequent activation of 
Raf, MEK1/2 and ERK1/2 ultimately 
leads to changes in gene expression 
due to the phosphorylation of down-
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Figure 2 • The conventional MAPK 
pathways. 
MAP kinases can be activated by  
a wide variety of extracellular stimuli 
through a cascade of upstream 
kinases that ultimately leads to the 
dual phosphorylation of a tyrosine (Y) 
and a threonine (T) residue in the 
activation loop of the MAPKs. Once 
phosphorylated, MAPKs phospho-
rylate cytoplasmic and nuclear 
proteins, which then control a wide 
variety of cellular processes.  
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Figure 3 • Different kinetics of ERK 
activation in PC12 cells. 
EGF treatment results in a rapid 
transient activation of ERK in the 
cytoplasm that involves Ras, and  
will lead to proliferation of the neuro-
endocrine PC12 cells ( left part). NGF 
stimulation induces a sustained ERK 
activation that can be viewed as the 
sum of the short-term Ras-mediated 
effects and a long lasting signal 
exerted via Rap1. The subsequent 
translocation of ERK into the 
nucleus leads to PC12 cell diffe-
rentiation into sympathetic neurons 
(right part). Nuclear and cytoplasmic 
ERK activity is displayed as gray 
colourings within the cells. Adapted 
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Figure 4 • The phosphotyrosine-
specific PTP superfamily. 
Schematic diagrams of represen- 
tative members for each classical 
receptor-type and non-receptor- 
type PTP subfamily, as classified by 
the features of their non-catalytic 
domains. For each of the 38 
mammalian PTP genes a single cor-
responding protein is listed except 
for the genes PTPN5 (STEP61 and 
STEP46) and PTPRR (PTPBR7,  
PTP-SL and PTPPBSγ, in bold). 
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Figure 5 • Regulation of MAPKs  
by tyrosine-specific MAPK 
phosphatases. 
Extracellular stimuli lead to the acti-
vation of MAPKs. Inactivation of 
MAPKs in the cytosol, and the pre-
vention of their nuclear transloca-
tion, is regulated in part through 
binding to the KIM-domain of MAPK-
PTPs and subsequent dephosphory-
lation of the phosphotyrosine residue 
within the MAPK. The association  
of the two proteins is regulated via 
reversible phosphorylation of a  
serine residue within the KIM-
domain by the concerted action  
of cAMP-dependent protein kinase 









J Biol Chem 1999, 274(17):11693-11700.
58 • Gronda M, Arab S, Iafrate B, 
Suzuki H, Zanke BW: Hemato-
poietic protein tyrosine 
phosphatase suppresses 
extracellular stimulus-regulated 
kinase activation. Mol Cell Biol 
2001, 21(20):6851-6858.
59 • Pulido R, Zúñiga A, Ullrich A: 
PTP-SL and STEP protein tyrosine 
phosphatases regulate the 
activation of the extracellular 
signal-regulated kinases ERK1 
and ERK2 by association through 
a kinase interaction motif. Embo J 
1998, 17(24):7337-7350.
60 • Zúñiga A, Torres J, Úbeda J, 
Pulido R: Interaction of mitogen-
activated protein kinases with 
the kinase interaction motif of 
the tyrosine phosphatase PTP-SL 
provides substrate specificity 
and retains ERK2 in the 
cytoplasm. J Biol Chem 1999, 
274(31):21900-21907.
61 • Muñoz JJ, Tárrega C,  
Blanco-Aparicio C, Pulido R: 
Differential interaction of  
the tyrosine phosphatases  
PTP-SL, STEP and HePTP with 
the mitogen-activated protein 
kinases ERK1/2 and p38alpha  
is determined by a kinase 
specificity sequence and 
influenced by reducing agents. 
Biochem J 2003, 372(Pt 1):193-201.
62 • Tárrega C, Blanco-Aparicio 
C, Muñoz JJ, Pulido R: Two clusters 
of residues at the docking groove 
of mitogen-activated protein 
kinases differentially mediate 
their functional interaction with  
the tyrosine phosphatases PTP-






















































63 • Huang Z, Zhou B, Zhang ZY: 
Molecular determinants of 
substrate recognition in 
hematopoietic protein-tyrosine 
phosphatase. J Biol Chem 2004, 
279(50):52150-52159.
64 • Buschbeck M, Eickhoff J, 
Sommer MN, Ullrich A: Phospho-
tyrosine-specific phosphatase 
PTP-SL regulates the ERK5 
signalling pathway. J Biol Chem 
2002, 277(33):29503-29509.
65 • Blanco-Aparicio C, Torres J, 
Pulido R: A novel regulatory 
mechanism of MAP kinases 
activation and nuclear trans-
location mediated by PKA and 
the PTP-SL tyrosine phosphatase. 
J Cell Biol 1999, 147(6):1129-1136.
66 • Paul S, Olausson P, 
Venkitaramani DV, Ruchkina I, 
Moran TD, Tronson N, Mills E, 
Hakim S, Salter MW, Taylor JR: 
The Striatal-Enriched Protein 
Tyrosine Phosphatase Gates 
Long-Term Potentiation and Fear 
Memory in the Lateral Amygdala. 
Biol Psychiatry ( in press) 2006.
67 • Valjent E, Pascoli V, 
Svenningsson P, Paul S, Enslen H, 
Corvol JC, Stipanovich A, 
Caboche J, Lombroso PJ, Nairn 
AC: Regulation of a protein 
phosphatase cascade allows 
convergent dopamine and 
glutamate signals to activate 
ERK in the striatum. Proc Natl 
Acad Sci U S A 2005, 102(2):491-496.
68 • Nika K, Hyunh H, Williams S, 
Paul S, Bottini N, Tasken K, 
Lombroso PJ, Mustelin T: 
Haematopoietic protein tyrosine 
phosphatase (HePTP) phospho-
rylation by cAMP-dependent pro-























Table 1 PTPRR nomenclature
Species Homo S. Mus M. Rattus N. Drosophila M.
Gene PTPRR Ptprr Ptprr PTP-ER
Chromosome 
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Figure 6 • Subcellular localisation 
of the different mouse PTPRR 
isoforms. 
The transmembrane proteins PTPBR7 
and PTP-SL are both localised at  
the Golgi apparatus and in late endo-
cytotic compartments. PTPBR7 is 
also present in early endosomes and 
at the plasma membrane, where it 
is subjected to proteolytic cleavage. 
The PTPPBSγ-42 and PTPPBSγ-37 
isoforms are cytosolic proteins. Grey 
arrows indicate general protein 
transport routes, but these are not 
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Spatio-temporal control of extracellular signal-regulated kinase (ERK) 
activity, a critical determinant of the cell’s response to growth 
factors, requires timely dephosphorylation of its regulatory tyrosine 
and/or threonine residue by MAPK phosphatases. We studied the 
physiological role of kinase interaction motif (KIM)-containing protein 
tyrosine phosphatases (PTPs) in the control of EGF- and NGF-induced 
ERK activity in neuroendocrine PC12 cells. We found a single KIM-
containing PTP to be endogenously expressed in rat PC12 cells: the 
transmembrane PTPRR isoform termed PCPTP1. Protein knock-down  
of PCPTP1, or fourfold overexpression of its mouse orthologue, PTPBR7, 
left EGF- and NGF-induced ERK1/2 activity in PC12 cells unaltered. 
Ectopic expression of cytosolic PTPRR isoforms, however, resulted in 
reduced EGF-induced ERK1/2 activity, an effect that was dependent 
on the phosphatase activity and the KIM-domain of these PTPs.  
The finding that robust changes in tyrosine-specific MAPK phosphatase 
expression levels have minor effects on temporal ERK1/2 activity 
control in PC12 cells suggests that dual-specificity MAPK phosphatases 
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Figure 1 • Tyrosine-specific MAPK 
phosphatases expressed in PC12 
cells. 
A) Schematic diagrams of STEP 
(STEP61, STEP46), HePTP and PTPRR 
(PTPBR7, PTP-SL, PTPPBSγ-42, 
PTPPBSγ-37) protein isoforms. Mouse 
isoform nomenclature is given on the 
right. Signal peptides (SP), prolinerich 
and PEST domains (PP), trans-
membrane segments (TM), kinase-
interacting motifs (KIM), hydrophobic 
regions (HR) and catalytic phospho-
tyrosine phosphatase domains (PTP) 
are indicated. 
B) Assessment of KIM-containing, 
tyrosine-specific PTP expression  
by RT-PCR. Rat protein nomenclature 
is indicated on the left, aligned with 
the diagrams of the mouse orthologs 
depicted in panel A). STEP and HePTP 
transcripts, as detected by RT-PCR 
(+) in mouse cerebrum (CRB) and 
spleen (SPL) RNA, respectively, are 
not found in PC12 cells. For rat 
PTPRR proteins (PCPTP1, PCPTP1-
Ce, PTPPBSγ) isoform-specific primer 
sets were used on rat cerebellum 
(CBL) and PC12 total RNA. Samples 
lacking RT enzyme (-) and appropri-
ate plasmids (p) served as negative 
and positive controls, respectively.  
A β-actin specific RT-PCR served as  














































Figure 2 • ERK activity profile is 
not affected by PCPTP1 depletion.  
A) RNAi-mediated knockdown of 
endogenous PCPTP1 in PC12 cells. 
PC12 cells stably expressing siRNA 
targeted to nucleotides 2380-2398 
in PCPTP1 cDNA  (pSR-2380) were 
generated via retroviral 
transduction. Empty vector (pSR) 
was used as control and PCPTP1 
knockdown was rescued by 
transduction of pSR-2380-con-
taining cells with a retroviral ex-
pression construct for the mouse 
ortholog PTPBR7. Equal amounts  
of protein from the resulting stable 
cell pools were subjected to im-
munoprecipitation using α-SL anti-
serum and captured proteins were 
analyzed on Western blots using 
monoclonal antibody 6A6.  
B) Transient and sustained ERK1/2 
signalling in wild type PC12 cells. 
After overnight serum deprivation, 
cells were stimulated with 100 ng/ml 
EGF (upper panels) or 50 ng/ml NGF 
(lower panels) for the indicated time 
points. Cell lysates were sub-jected 
to Western blot analysis and 
phospho-ERK1/2 signals (pERK1, 
pERK2) were detected using a che-
miluminescence imaging system. 
The same blot was reprobed with 
total ERK1 antibody to correct for 
loading differences.  
C) Transient ERK activity is not af-
fected in PCPTP1 knockdown cells. 
Serum-starved cells were stimulated 
with 10 ng/ml EGF for 2 or 5 min, 
respectively, and harvested. Relative 
phospho-ERK1/2 levels in the pro-
tein lysates, determined as above, 


























































from three independent experiments. 
D) PCPTP1 knockdown in PC12 cells 
does not significantly alter ERK 
activity at reduced levels of EGF. 
Serum starved cells were stimulated 
with 0.075 ng/ml EGF for the indi-
cated time points and relative 
phospho-ERK1/2 levels were deter-
mined as before. Results are mean 












































PTPRR effects on ERK activity involve KIM-mediated interactions
The	binding	of	KIM-domain-containing	phosphatases	to	their	MAPK	targets	
27 • Yao H, York RD, Misra-Press 
A, Carr DW, Stork PJ: The cyclic 
adenosine monophosphate-
dependent protein kinase (PKA) 
is required for the sustained 
activation of mitogen-activated 
kinases and gene expression by 



























































Figure 3 • Expression of PTPRR 
isoforms in PC12 cells.  
A) PC12 cells were retrovirally trans-
duced with expression constructs 
for mouse PTPRR isoforms, or mock-
transduced. Equal amounts of cell 
lysates were subjected to 10% SDS-
PAGE and immunoblotting. Rat 
PCPTP1, mouse PTPBR7 and mouse 
PTPPBSγ ( indicated on the left) were 
detected using 6A6 antibody. Mole-
cular size markers are indicated on 
the right. The arrow indicates a 
cross-reactive ~50kDa background 
band.  
B) Quantitative representation of 
PTPRR expression levels as deter-
mined in A. PTPRR levels were 
corrected for loading differences 
using monoclonal α-tubulin antibody 
E7 immunostaining (not shown) as  
a control. Results are the mean 
values ± SEM of four individual pools 
of cells.  
C) Subcellular localization of stably 
expressed PTPRR protein isoforms in 
the transduced PC12 cells as deter-
mined by fluorescence microscopy 










Figure 4 • PTPRR effect on growth 
factor-induced ERK signalling.  
A) PC12 cells stably expressing 
PTPPBSγ show reduced transient 
ERK1/2 activity. Serum-starved 
pools of mock-transduced, PTPBR7 
expressing or PTPPBSγ expressing 
cells were treated with 100 ng/ml 
EGF for 2 or 5 min before being 
lysed. Proteins were size-separated 
and immunoblotted. Representa- 
tive images of phospho-ERK1/2 
(upper panel) and total ERK1  
( lower panel) immunoreactivity  
are depicted.  
B) Reduced transient ERK activity  
in PTPPBSγ expressing cells. Quan-
titative representation of relative 
phospho-ERK1/2 levels in cells 
stimulated with EGF for two or five 
minutes. Results are presented as 
mean values ± SEM from six inde-
pendent experiments (Student’s t-
test, *p<0.008).  
C) Increased PTPRR levels have no 
effect on NGF-induced ERK1/2 
activity. Serum starved PC12 cell 
pools stably expressing PTPBR7  
or PTPPBSγ were stimulated with  
50 ng/ml NGF for the indicated  
time points ( in min). Cells were then 
lysed and phospho-ERK1/2 were 
analysed on Western blots as in 
panels A-B. Results are the mean ± 



























































Figure 5 • Assessment of PTPRR 
KIM domain phosphorylation.  
A) Lysates of PTPPBSγ expressing 
cells after overnight serum star-
vation (t=0) and subsequent treat-
ment with EGF, NGF or forskolin 
were subjected to immunoprecipi-
tation with monoclonal antibody 
6A6, and captured proteins were 
analyzed on blot using a phospho-
PKA substrate antibody (upper 
panel) and 6A6 (lower panel). It  
was ascertained that the phospho-
PKA substrate antibody remained 
unreactive towards PTPPBSγ mutant 
S94A (data not shown).  
B) Quantitative representation of 
phospho-PTPPBSγ levels deter-
mined as in A. Results, expressed  
as the ratio of the signals obtained 
with the phospho-PKA substrate 
antibody and the PTPRR antibody, 
are presented as mean values ± SEM 
(n=3, Student’s t-test, *p<0.02).  
C) Representative image of PTPBR7 
proteins, immunoprecipitated with 
antibody 6A6 from PTPBR7 
expressing cells that received the 
indicated stimuli, as detected with 
phospho-PKA substrate antibody 
(upper panel) or 6A6 (lower panel). 
D) Quantitative representation of 
phospho-PTPBR7 levels as deter-
mined in C. Results are presented  
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Figure 6 • Wild type and non-
phosphorylatable PTPPBSγ affect 
ERK activity. 
A) Expression analysis of wild type 
and mutant PTPPBSγ proteins. Equal 
amounts of protein from PC12 cells 
stably expressing wild type (WT) or 
mutant (ΔKIM, D309A, S94A/T114A, 
and C343S) PTPPBSγ were subjec-
ted to SDS-PAGE and immunoblot 
analysis using antibody 6A6. 
B) EGF-induced ERK1/2 activity  
in PC12 cells stably expressing 
PTPPBSγ protein variants. Serum 
starved cells that stably express 
PTPPBSγ mutants were stimulated 
with 10 ng/ml EGF for 2 or 5 min, 
and lysed. Relative phospho- 
ERK1/2 levels were determined via 
immunoblot analysis as described  
in the legends to Fig. 2. Results  
are presented as mean values ± SEM 
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The neuronal protein tyrosine phosphatases encoded by mouse gene 
Ptprr (PTPBR7, PTP-SL, PTPPBSγ-42 and PTPPBSγ-37) have been impli-
cated in mitogen-activated (MAP) kinase deactivation on the basis of 
transfection experiments. To determine their physiological role in vivo, 
we generated mice that lack all PTPRR isoforms. Ptprr-/- mice were 
viable and fertile, and not different from wildtype littermates regarding 
general physiology or explorative behaviour. Highest PTPRR protein 
levels are in cerebellum Purkinje cells, but no overt effects of PTPRR 
deficiency on brain morphology, Purkinje cell number or dendritic 
branching were detected. However, MAP kinase phosphorylation levels 
were significantly altered in the PTPRR-deficient cerebellum and cere-
 brum homogenates. Most notably, increased phospho-ERK1/2 immuno-
staining density was observed in the basal portion and axon hillock of 
Ptprr-/- Purkinje cells. Concomitantly, Ptprr-/- mice displayed ataxia 
characterized by defects in fine motor coordination and balance skills. 
Collectively, these results establish the PTPRR proteins as physiological 
regulators of MAP kinase signalling cascades in neuronal tissue and 
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Figure 1 • Ptprr targeted 
disruption.  
A) The structure of mouse gene Ptprr 
(upper) and the targeting strategy 
( lower) is depicted. Genomic DNA is 
represented by a grey horizontal  
bar and exons are depicted as verti-
cal bars with exon number or name 
indicated above. The three distinct 
transcription start sites [19] are 
represented by hooked arrows.  
The PTPBR7 transmembrane domain 
is encoded within exons 5 and 6,  
the KIM domain codons originate 
from exons 6 and 7, and the catalytic 
PTP domain coding region spans 
exons 8-14. DNA stretches used to 
obtain homologues recombination 
are boxed and named 5’- and 3’-arm, 
respectively. A neomycin resistance 
cassette (Neo) in the opposite trans-
criptional orientation replaces exon 
6 in the targeting construct, which  
at the 5’ end also harbours the 
diphtheria toxin cassette (DT) for 
negative selection purposes. Two-
headed arrows indicate BamHI 
restriction fragments detected by 
diagnostic probes 5’p and 3’p  
on Southern blots.  
B) Southern analysis of BamHI-diges-
ted genomic DNA from liver of wild-
type (+/+), heterozygous (+/-), and 
Ptprr-/- (-/-) mice. Hybridisation 
with the 5’ ( left) and 3’ (right) dia-
gnostic probes revealed the wildtype 
8.6-kbp fragment and a mutant 2.0- 
or 6.9-kbp fragment, respectively.  
C) Northern analysis of total RNA ex-
tracted from cerebrum (cbr) or cere-
bellum (cbl) of wildtype, heterozy-
gous, or Ptprr-/- mice using a probe 






























































D) Western blot analysis of proteins, 
immunoprecipitated by monoclonal 
antibody 6A6 from brain extracts of 
wildtype, heterozygous, and Ptprr-/- 
mice, using rabbit α-SL antiserum. 
Upper bands of around 75, 70 and 
65 kDa in size represent PTPBR7-
derived processed proteins; the 65 
kDa species may also contain PTP-
SL; and the smaller immunoreactive 










Figure 2 • Normal brain and cere-
bellum Purkinje cell morphology in 
Ptprr-/- mice. Haematoxilin/eosin 
stained sagittal brain sections 
displaying similar cortex, striatum, 
corpus callosum, fimbria fornix and 
hippocampus layering and morpho-
logy in wildtype (A) and Ptprr-/- (B) 
mice are shown. Cerebellum cortex 
granular, Purkinje and molecular 
layers in wildtype (C) and Ptprr-/- 
(D) mice are similar as well. 
Immunostaining for PTPRR revealed 
specific staining of Purkinje cells in 
wildtype (E), but not Ptprr-/- (F), 
mice. Purkinje cell staining with cal-
bindin (28 kD) antibody demonstra-
ted very similar cell numbers and 
branching morphology in both wild-
type (G,I) and Ptprr-/- (H,J) mice. 
Bars represent 500 (A,B), 425 (C,D), 






























































Figure 3 • Altered MAPK phos-
phorylation levels in Ptprr-/- 
mouse brain. 
Degree of ERK1/2 (A), p38 (B) and 
JNK1/2 (C) biphosphorylation in 
cerebellum and cerebrum of wildtype 
(+/+, white bars) and Ptprr-/- (-/-, 
black bars) mice as determined by 
Western analyses of tissue lysates 
from individual mice (n=7 for each 
tissue and genotype group) using 
phospho-specific antibodies. Repre-
sentative examples (three out of the 
seven for each tissue and genotype 
group) of phosphorylated ERK1/p44 
and ERK2/p42 (pERK) and total 
ERK1/2 (totERK) immunofluorescent 
signals are depicted above the cor-
responding bars. Phosphorylated 
ERK1/2, p38 and JNK1/2 signals 
were normalized to total ERK1/2, 
p38 and JNK1/2 levels, respectively, 
and plotted as relative phospory-
lation levels. Results are the mean  
± SEM of 7 samples per group and 
are representative of at least 3 inde-













































29 • Zsarnovszky A, Belcher SM: 
Spatial, temporal, and cellular 
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Figure 4. ERK1/2 
hyperphosphorylation in Ptprr-/- 
cerebellum Purkinje cells. 
Immunostaining for biphosphory-
lated, active ERK1/2, confined  
to the basal portion and the axon 
hillock of wildtype (A) and Ptprr-/- 
(B) Purkinje cells. Bars represent  
50 μm in A1 and B1, and 20 μm in  
A2 and B2 (for A2-A5 and B2-B5).  
C) Quantification of phospho-ERK1/2 
staining density demonstrated a sig-
nificant increase of 37% in Ptprr-/- 
Purkinje cells (-/-) as compared to 












































































































Figure 5 • PTPRR effects on 
ERK1/2 signalling pathways  
are downstream of MEK.  
MEK1/2 (A), Elk-1 (B) and S6 
ribosomal protein (C) phosphory- 
lation levels were analysed using 
phospho-specific antibodies on  
blots containing cerebellum or ce-
rebrum tissue lysates of indivi- 
dual wildtype (+/+, white bars)  
and Ptprr-/- mice (-/-, black bars). 
Results, representative for 3 
independent experiments, were 
normalized to total MEK, Elk, or 
tubulin protein levels, respectively, 
and are presented as the mean  































































































Figure 6 • Motor coordination and 
balance defects in Ptprr-/- mice.  
A) Rotarod. The time wildtype (+/+, 
white bars) and Ptprr-/- (-/-, black 
bars) mice remained on the acce-
lerating rotarod, as measured during 
3 trials, is depicted as mean ± SEM 
(*p < 0.015).  
B) Rope grip test. The time wildtype 
and Ptprr-/- mice (n=9 per group) 
were holding onto a horizontally 
tightly suspended rope, measured 
during 3 trials, is depicted as mean  
± SEM (*p <0.031).  
C) The percentage of mice falling  
off during the 3 Rope grip trials is 
shown for both genotypes (Chi-
square test, *p <0.01). Parallel bars. 
The mean ± SEM number of slips that 
mice show while traversing parallel 
bars (D, *p <0.04) or a single bar  
(E, *p <0.05) during 2 trials is indi-
cated for both genotypes.  
F) The percentage of mice falling  
off the single bar during the 2 trials 
is shown for each group (Chi-square 
test, *p <0.02).  
G) Hindlimb gait. Aberrations in 
hindfoot placing of Ptprr-/- (-/-) 
mice and wildtype controls (+/+) 
that were walking through an alley 
are depicted as mean “% foot mis-
match” ± SEM (*p <0.002).  
H) Activity cage. General basal 
activity of wildtype (+/+, open 
circles) and Ptprr-/- (-/-, filled 
squares) mice (n=8 per group) was 
measured overnight for fifteen hours 
continuously, and is expressed as 
mean total counts per 60 minutes ± 
SEM. (Anova repeated measures, 
F(1,14) = 13.831; *p <0.002). For A), 
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PCR product (size in bp) 5’primer 3’primer
Fragment intron 5 (2075) cgttgagtttatgtgtactgcgtg cgggatcccgacatgagggcttctgtgag
Fragment intron 6 (8570) cgttgagtttatgtgtactgcgtg ctttcattctacgtgtatttgcctg
5’ diagnostic probe (349) cgttgagtttatgtgtactgcgtg cagaataacatcgaagaagagtctg
3’ diagnostic probe (1272) cctggcttgcattacttcatc ctttcattctacgtgtatttgcctg
Wildtype Ptprr allele (524) gctcaacccaactggaaatac agggtccacaaccacgttca















 • Supplemental Materials and Methods Supplementary Table S1
Primers used for genotyping of cells 
and mice. Underlined sequence is  
a BamHI restriction site. Fragment 
intron 5 has been BglII-BamHI diges-
ted resulting in a 1725bp fragment. 
Fragment intron 6 has been HindIII-
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Figure S1 • Analysis of proteins, 
immunoprecipitated from extracts  
of wildtype, heterozygous, or 
knockout mouse brain by a poly-
clonal antibody raised against the 
extracellular domain of PTPBR7,  

















4 • Multimerisation of receptor-type protein 
tyrosine phosphatases PTPBR7 and PTP-SL 
attenuates enzymatic activity 
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Dimerisation of receptor-type protein tyrosine phosphatases (RPTPs) 
represents an appealing mechanism to regulate their enzymatic activity. 
Studies thus far mostly concern the dimerisation behaviour of RPTPs 
possessing two tandemly oriented catalytic PTP domains. Mouse gene 
Ptprr encodes four different protein isoforms (i.e. PTPBR7, PTP-SL  
and PTPPBSγ-42/37) that contain a single PTP domain. Using selective 
membrane permeabilisation we here demonstrate that PTP-SL, like 
PTPBR7, is a single membrane-spanning RPTP. Furthermore, these 
two receptor-type PTPs constitutively formed homo- and heteromeric 
complexes as witnessed in chemical cross-linking and co-immuno-
precipitation experiments, in sharp contrast to the cytosolic PTPPBSγ-42 
and PTPPBSγ-37 PTPRR isoforms. This multimerisation occurs inde-
pendently of the PTP domain and requires the transmembrane domain 
and/or the proximal hydrophobic region. Using overexpression of a 
PTPBR7 mutant that essentially lacks the intracellular PTP domain-
containing segment, a monomer-mimicking state was forced upon full-
length PTPBR7 immunoprecipitates. This resulted in a significant 
increase in the enzymatic activity of the PTPRR PTP domain, which 
strengthens the notion that multimerisation represents a general 
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Figure 1 • Characterisation of  
the α-SL-specific antiserum.  
A) Schematic representation of  
the different mouse PTPRR protein 
isoforms. Signal peptide (SP), 
hydrophobic regions (HR1, HR2), 
kinase-interacting motif (KIM), 
catalytic phosphotyrosine phos-
phatase domain (PTP) and the 
segments recognised by the α-BR7 
and α-SL-specific antisera and the 
monoclonal antibody 6A6 are 
indicated. HR2 functions as a ‘stop-
transfer signal’ in the receptor- 
type PTPBR7 isoform. Whether HR2 
also is a transmembrane-spanning 
region in PTP-SL has been addres- 
sed in the current study.  
B) Total lysates of HeLa cells 
transiently transfected with 
expression plasmids pSG5/PTPBR7, 
pSG5/PTP-SL or pSG5/PTPPBSγ 
were analysed on Western blot using 
monoclonal antibody 6A6 (left panel) 
and rabbit polyclonal α-PTP-SL-
specific antiserum (right panel). 
Rabbit polyclonal α-BR7 antiserum 
only detected the PTPBR7 isoform 
(data not shown). Please note that 
the PTPPBSγ mRNA codes for both 
PTPPBSγ-42 and PTPPBSγ-37 by vir-
tue of alternative translation start 
codons [21]. Molecular size markers 









Figure 2 • PTP-SL is a trans-
membrane protein.  
A) HeLa cells selectively perme-
abilised with digitonin or Triton X-
100 were stained with α-PDI anti-
serum to detect endogenous ER 
lumenal protein disulphide 
isomerase ( left panels) or with  
α-Lamp-1 antiserum to detect  
a cytosolic epitope in lysosome-
associated membrane protein-1 
(right panels).  
B) HeLa cells expressing PTPBR7-
VSV were permeabilised with the 
indicated detergents and 
subsequently co-immunostained 
with mouse monoclonal α-VSV 
antibody and rabbit α-BR7 
antiserum. Anti-VSV staining always 
resulted in fluorescent signals at  
the plasma membrane, vesicular 
structures and the Golgi apparatus 
( left panels), as for the α-BR7 
antiserum on Triton X-100 permeabi-
lised cells ( lower middle panel). In 
digitonin treated cells α-BR7 reac-
tivity was only present on the plasma 
membrane (upper middle panel), 
confirming that PTPBR7 is a type I 
transmembrane protein [24].  
C) HeLa cells expressing PTP-SL-VSV 
were treated with the indicated 
detergents and then co-immuno-
stained with monoclonal α-VSV 
antibody and rabbit α-PTP-SL-
specific antiserum. For both perme-
abilisation conditions α-VSV staining 
revealed Golgi and vesicular 
structures ( left panels), while the α-
PTP-SL-specific signal as observed 
in Triton X-100 treated cells ( lower 
middle panel) is reduced to 
background levels (as observed in 









































































Figure 3 • Homo- and hetero-
multimerisation of PTPRR 
isoforms.  
A) Intact COS-1 cells transiently 
transfected with pSG5/PTPBR7 
were treated with (+) or without  
(-) BS3 crosslinker, and lysed. 
Cleared lysates were subjected  
to 6% SDS-PAGE and immunoblot-
ted using monoclonal antibody 6A6. 
PTPBR7 monomers are indicated 
with an arrow, dimers with a filled 
arrowhead and multimers with an 
open arrowhead. Molecular size 
markers are indicated on the right.  
B) Schematic representation of  
the proteins used in the co-immuno-
precipitation experiments depicted 
in C). Coiled-coil domains (CC), 
signal peptide (SP), hydrophobic 
region (HR), transmembrane domain 
(TM), kinase-interacting motif (KIM), 
catalytic domain (PTP) and the C-
terminal HA or VSV epitope tags (E) 
are indicated.  
C) COS-1 cells were transiently 
transfected with HA- or VSV-tagged 
PTPRR expression plasmids in the 
indicated combinations. Upon 
immunoprecipitation (IP) of HA-
tagged proteins from cleared lysa-
tes (CL) using monoclonal antibody 
12CA5 (monoHA), co-precipitating 
proteins were detected using po-
lyclonal α-VSV antibody on immu-
noblots (IB). The IP procedure was 
verified on separate immunoblots 





















































































































Figure 4 • Mapping of the multi -
merisation domains in PTPBR7.  
A) Schematic representation of 
mutant PTPBR7 proteins used in  
the co-immunoprecipitation expe-
riments depicted in B). Nomen-
clature, encompassed or deleted (Δ) 
amino acid regions, and the position 
of signal peptide (SP), hydrophobic 
region (HR), transmembrane domain 
(TM), kinase-interacting motif (KIM), 
catalytic domain (PTP) and C-termi-
nal epitope tag (E) are indicated for 
each mutant. Schematic represen-
tations of epitope-tagged BICD1, 
PTP-SL and PTPPBSγ proteins were 
given in Figure 3B.  
B) Transfected COS-1 cells expres-
sing the indicated combinations of 
HA- or VSV-tagged proteins were 
lysed (CL). Upon immunoprecipita-
tion of HA-tagged proteins (IP: 
monoHA; upper panels), which was 
verified using a polyclonal anti-HA 
antiserum (IB: polyHA; upper 
panels), co-precipitating proteins 
were detected using poly α-VSV 
antiserum (IB: polyVSV; lowest 
panels). In a parallel experiment 
(data not shown) PTPBR7-T-ΔHR-VSV 
was co-precipitating with full- length 
HA-tagged PTPBR7 and PTP-SL  
but not with HA-tagged PTPPBSγ  
and BICD1, which served as negative 
control. Background signals due to 
non-specific binding of PTPBR7-H-
ΔHR-VSV are indicated by an asterisk. 
Molecular size markers are indicated 
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Figure 5 • PTPRR binding domains 
in PTP-SL.  
A) Schematic representation of 
mutant PTP-SL proteins used in co-
immunoprecipitation experiments. 
Nomenclature, encompassed or 
deleted (Δ) amino acid regions, and 
the position of hydrophobic region 
(HR), transmembrane domain (TM), 
kinase-interacting motif (KIM), cata-
lytic domain (PTP) and C-terminal 
epitope tags (E) are indicated. Sche-
matic representations of epitope-
tagged PTPBR7 mutants and PTPPBSγ 
proteins were given in Figures 4A 
and 3B, respectively.  
B) COS-1 cells ectopically 
expressing the indicated HA- and 
VSV-tagged proteins were lysed 
(CL). Upon immunoprecipitation  
of HA-tagged proteins (IP: monoHA), 
which was verified on blot using 
polyclonal anti-HA antiserum (IB: 
polyHA; upper panels), co-precipita-
ting proteins were detected using 
polyclonal α-VSV antiserum (IB: 
polyVSV; lower panels). Specific and 
background signals are indicated by 
arrowheads and asterisks, respec-
tively. The BICD1 protein served as  
a negative control. Molecular size 




























Figure 6 • Protein tyrosine phos-
phatase activity is reduced upon 
multimerisation.  
A) Transfected COS-1 cells expres-
sing Myc-ERK2 together with 
PTPBR7-VSV and/or PTPBR7-T-VSV 
were serum-starved overnight, 
stimulated with EGF and 
subsequently lysed. VSV-tagged 
protein levels ( IB: polyVSV) in  
the cleared lysate (CL) and phospho-
rylated (IB: pERK1/2) and total ( IB: 
polyMyc) Myc-ERK2 protein levels 
upon immuno-precipitation using 
antibody 9E10 (IP: monoMyc) were 
determined by immunoblot analysis.  
B) Quantitative representation of 
relative Myc-ERK2 phosphorylation 
levels as determined in A). Results 
are presented as mean values ± SEM 
(n=3, * p<0.005, ** p<0.045).  
C) Lysates from COS-1 cells 
expressing PTPBR7-VSV and/or 
PTPBR7-T-VSV were subjected to 
immuno-precipitation (IP) using 
antibody 6A6. Protein amounts  
in the cleared lysate (CL) and the 
immuno-precipitate were quantified 
by immunoblot analysis using poly-
clonal α-VSV antiserum (IB: polyVSV).  
D) Immunoprecipitates described  
in C) were used in a fluorescent in 
vitro phosphatase activity assay 
exploiting DifMUP as a substrate. 
The steady state enzymatic activities 
measured for the given protein com-
binations were normalised for the 
amount of precipitated PTPBR7-VSV, 
with the exception of the values  
for precipitates from cells solely 
transfected with the PTPBR7-T-VSV 
expression construct (BR7-T). 







































































values ± SEM (*p < 0.009).  
E) Lysates from COS-1 cells expres-
sing PTPBR7-VSV, PTPPBSγ-VSV or 
PTPBR7-C/S-VSV were subjected to 
immunoprecipitation (IP) using  
a monoclonal antibody against the 
VSV-G epitope tag. Proteins were 
released from the beads using VSV-G 
peptide and analysed on immuno-
blots and in fluorescent phosphatase 
activity measurements. Enzymatic 
activities were normalised for PTP 
protein content. Results (n=4) are 
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Differentiation and survival of neuronal cell types relies on adequate 
neurotrophin signalling. The receptor tyrosine kinase TrkA belongs  
to the neurotrophin receptor family and specifically binds nerve growth 
factor, NGF. Activation of signalling pathways downstream of TrkA 
involves the autophosphorylation of several key tyrosine residues,  
the dephosphorylation of which implies involvement of protein tyrosine 
phosphatases, PTPs. Here, we demonstrate that the two transmem-
brane products encoded by the gene Ptprr (PTPBR7 and PTP-SL) are 
able to bind and dephosphorylate TrkA and its p41 cleaved fragment. 
This association is independent of the phosphatase domain, requires 
the presence of the hydrophobic segments, and does not occur with 
the highly related neurotrophin receptor TrkB. Strikingly, PTPBR7 and 
PTP-SL also promote the maturation and cell-surface expression of 
TrkA. These effects on binding, dephosphorylation and maturation  
of TrkA are not exerted by the cytosolic Ptprr gene products. These 
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Co-immunoprecipitations and immunoblot analyses
COS-1	cells	on	a	10-cm	dish	were	harvested	24	h	after	transfection	and	the	
obtained	lysates	served	in	immunoprecipitation	and	immunoblot	experiments	
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Figure 1 • Co-immunoprecipitation 
of TrkA with PTPBR7 and PTP-SL. 
A) Schematic representation of the 
proteins used in the experiments. 
Signal peptide (SP), leucine-rich 
repeat (LRR), immunoglobulin-like 
domain (Ig-like), transmembrane 
domain (TM), catalytic tyrosine 
kinase domain (PTK), hydrophobic 
region (HR), kinase-interacting  
motif (KIM), catalytic phosphotyro-
sine phosphatase domain (PTP) and 
C-terminal HA or VSV tags (T) are 
indicated.  
B) HA-tagged PTPRR isoforms were 
co-expressed with VSV-tagged TrkA 
(left panels) or TrkB (right panels)  
in COS-1 cells. Upon immunoprecipi-
tation of HA-tagged proteins (IP: 
12CA5), co-precipitating proteins 
were detected using α-VSV antibody 
(IB: polyVSV). Expression and preci-
pitation of HA-tagged proteins was 
verified on blots using a polyclonal 
anti-HA tag antiserum (IB: polyHA). 
Note that the p41 TrkA cleavage 
product ( indicated with an arrow  
in the lower left panel) is not detec-
ted in the cell lysate (CL). Size 



















































Figure 2 • In vitro tyrosine dephos- 
phorylation of TrkA by the PTPRR 
phosphatase domain. 
A) COS-1 cells expressing TrkA-VSV 
were treated with BpV(phen) before 
being lysed. Immuno-precipitated 
VSV-tagged proteins (IP: P5D4) were 
incubated with active (WT) or 
inactive (DA/CS) recombinant GST-
PTPRR phosphatase domain fusion 
proteins and then analysed on 
Western blots with monoclonal  
α-phosphotyrosine (IB: PY20) and 
polyclonal α-VSV antibodies. Arrows 
depict the tyrosine-phosphorylated 
and non-phosphorylated forms of 
p41 TrkA (p41) and the immature 
(p110) and mature (p140) full - length 
TrkA species. Size markers ( in kDa) 
are indicated in between the panels.  
B) Purified recombinant GST fusion 
proteins that were used in A), 
containing active (WT) or mutant 
(DA/CS) PTPRR phosphatase 
domain, were analysed on Western 
blot with rabbit polyclonal α-SL 
antibody. Size markers ( in kDa) are 









Figure 3. Effects of PTPRR isoform 
expression on TrkA tyrosine phos-
phorylation. 
A) COS-1 cells expressing active 
(WT) or inactive (C/S) PTPRR 
isoforms in combination with VSV-
tagged TrkA were treated prior to 
lysis with NGF. Cell lysates (CL) were 
immunoblotted using anti-PTPRR 
monoclonal antibody 6A6. Immuno-
precipitated TrkA (IP: P5D4) was 
quantified on blot ( IB: α-VSV) and 
simultaneously site-specific phospho-
rylation levels were monitored using 
either pY680/681 or pY490 phospho-
specific antibodies. Arrows on the 
right indicate the positions of the 
various TrkA species. Size markers 
( in kDa) are indicated on the left. 
Ratio-imaging of immunoblot sig-
nals from three independent expe-
riments allowed the quantitative 
analysis of relative phosphorylation 
levels at positions Y490 (B-D) and 
Y680/681 (E-G) in the three distinct 
TrkA species: p140 (B, E), p110 (C, F) 
and p41 (D, G). All results are presen-
ted as mean values ± SEM (n=3) for 
the various PTPRR isoforms that 
were co-expressed with TrkA (indica-
ted below graphs C, F and G only). 
Asterisks in panels B) (* p<0.007), 
C) (* p<0.008), D) (* p<0.022; ** 
p<0.05), E) (* p<0.001; ** p<0.036) 
and G) (* p<0.032) reflect signi-
































































































PTPBR7 and PTP-SL promote TrkA maturation
Strikingly,	we	noted	that	BpV(phen)	treatment	of	cells	resulted	in	a	markedly	
lower	amount	of	mature,	p140	TrkA	as	compared	to	untreated	cells	(comp.		
Figure 4 • PTPBR7 and PTP-SL 
promote TrkA maturation. 
A) TrkA-VSV, immunoprecipitated 
(IP: P5D4) from COS-1 cells co-
expressing wild type (WT) or inactive 
(C/S) PTPBR7, was treated with 
PNGaseF or EndoH and subsequently 
immunoblotted using polyclonal α-
VSV antibody (IB: polyVSV). TrkA 
species, including the 80 kDa core 
protein, are indicated by arrows on 
the right. 
B) Quantitation of the p140 TrkA 
steady state levels relative to that of 
p110 TrkA as determined in three 
independent immunoblot experiments 
like the one depicted in Figure 3A. 
Co-expressed PTPRR isoforms are 
indicated below the bars. Results are 
presented as mean values ± SEM 
(n=3, Student’s t-test, * p<0.007). 
C) COS-1 cells expressing VSV-tag-
ged TrkA alone (-), or TrkA together 
with wild type (BR7-WT) or in-active 
(BR7-C/S) PTPBR7, were cultured  
in the presence of [35S]methionine-
[35S]cysteine for 20min and subse-
quently chased with fresh medium 
for the indicated time periods before 
being lysed. Immunoprecipitated 
TrkA was subjected to SDS-PAGE and 
blotting, and radioactivity was 
detected using a Molecular Imager 
device. Arrows on the right indicate 
the positions of the p140 and p110 
TrkA species. 
D) Maturation of de novo synthe-
sized TrkA, as determined in (C), 
expressed in arbitrary units (a.u.) 
that reflect the ratio of p140 and 
p110 signals. 
E) TrkB-VSV and TrkA-VSV precursors 


















































head) were immunoprecipitated (IP: 
P5D4) from COS-1 cells co-expres-
sing wild type (WT) or inactive (C/S) 
PTPBR7. Detection on immunoblots 
was using polyclonal α-VSV anti-
body (IB: polyVSV). Expression of 
PTPBR7 proteins in the lysates (CL) 
is visualised on blots using mono-
clonal antibody 6A6. 
F) COS-1 cells expressing TrkA-VSV 
in combination with wild-type (WT) 
or inactive (C/S) PTPBR7, or with 
PTPPBSγ, were surface-biotinylated 
for 45 min at 4°C before being lysed. 
Immunoprecipitated TrkA-VSV (IP: 
P5D4) was analysed on blots using 
fluorescently labelled streptavidin 
(upper panel) and α-VSV antiserum 
(middle panel) allowing dual detec-
tion on an Odyssey infrared imager. 
Expression of PTPRR isoforms in cell 
lysates (CL) was verified on separate 
blots using polyclonal α-SL antibody 
( lower panel). Arrows on the right 
indicate the various TrkA species. 
Size markers ( in kDa) are indicated 
on the left. 
G) Neuro-2A cells expressing active 
(WT) or inactive (C/S) PTPBR7 in 
combination with VSV-tagged TrkA 
were treated prior to lysis with NGF. 
Cell lysates (CL) were immunoblot-
ted using anti-PTPRR monoclonal 
antibody 6A6. Immunoprecipitated 
TrkA (IP: P5D4) was quantified on 
blot ( IB: α-VSV) and simultaneously 
site-specific phosphorylation levels 
were monitored using either 
pY680/681 or pY490 phospho-
specific antibodies. Arrows on the 
right indicate the positions of the 
various TrkA species. Size markers 
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Figure 1 • Schematic depiction  
of the likely subcellular localisa-
tion of homo- and heteromeric 
PTPRR proteins. 
The hydrophobic region (HR), KIM 
sequence and catalytic PTP domain 
in each subunit are indicated. The 
transmembrane PTPBR7 and PTP-SL 
are predicted to exist as mono- 
mers and homo/heteromeric com-
plexes at the Golgi and vesicular 
structures from the endocytotic  
compartment. At the plasma mem-
brane and early endosomes only 
PTPBR7 homomers and monomers 
are expected. The non-transmem-
brane PTPPBSγ-42 and PTPPBSγ-37 
isoforms do not form multimers  
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Figure 2 • Illustration of the 
localisation of the different TrkA 
protein variants in the cell. 
The protein tyrosine kinase catalytic 
domain (PTK) is indicated for the 
immature (p110), mature (p140) and 
cleaved (p41) TrkA isoforms. Enzyma-
tically active PTPBR7 and PTP-SL aid 
in the maturation of TrkA, presuma-
bly by chaperoning the kinase on its 
route from the ER membrane through 
the Golgi apparatus towards the  
cell surface. Especially the p41 frag-
ment that is generated following 
cleavage (symbolized by a scissor) 
of TrkA at the cell surface strongly 
associates with PTPBR7 and, after 
translocation to late endosomes, 
PTP-SL (chapter 5). The cytosolic 
isoforms PTPPBSγ-42 and PTPPBSγ-37 
do not bind TrkA. As yet it is unclear 
whether PTPBR7 and PTP-SL bind to 
the activated TrkA dimer or that they 
rather associate with monomeric 
TrkA. For a schematic overview of 
the localisation of the different 
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Figure 3 • Graphical display of a 
model for the influence of recep-
tor-type PTPRR isoforms on 
cellular phospho-TrkA dynamics. 
Curves representing the hypothetical 
levels of cellular TrkA phospory-
lation at different time points after 
treatment of cells with a fixed 
amount of NGF (arrow). Mock trans-
fected cells (Mock) with endogenous 
levels of PTPRR and TrkA proteins 
will display a “basal” phospho-TrkA 
signal that will be lower than cells 
overexpressing TrkA (+TrkA). Over-
expression of receptor-type PTPRR 
isoforms (+PTP) will minimally affect 
basal phospho-TrkA levels, because 
the rise in PTPs is paralleled by a 
rise in TrkA level at the cell surface. 
Consequently, NGF treatment ( indi-
cated by an arrow) of +PTP cells will 
lead to a rise in phospho-TrkA level 
that is higher than that obtained in 
Mock cells. This will also be the case 
in TrkA-overexpressing cells. The 
subsequent down-regulation of the 
phospho-TrkA signal, however, will 
be much quicker in PTP overexpres-
sing cells than that in TrkA overex-
pressors. Thus, the net effect of 
increased PTP levels and concomi-
tant TrkA upregulation is predicted 
to be a higher NGF sensitivity wit-
hout altered basal phospho-TrkA 
levels and a subdued downstream 
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